California-based biotech company Ligand Pharmaceuticals has acquired CyDex Pharmaceuticals and its Captisol solubility-enhancing technology. CyDex’s pipeline includes a Captisol-enhanced budesonide/azelastine nasal spray. Ligand will operate CyDex as a wholly-owned subsidiary. Read the company’s press release.
CyDex acquired by Ligand Pharmaceuticals
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
